New treatment for moderate to severe atopic dermatitis shows promising long-term results

Professional, doctor. Scientist with microscope

Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab—a novel, patient-tailored monoclonal antibody therapy—showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped, Mount Sinai researchers reported in The Lancet.

How a viral toxin may exacerbate severe COVID-19

Previous article

Why Mid-Career Changers are the Answer to Tech Talent Shortages

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations